Index Options
CME Group
Nasdaq
Cboe
TradingView
Wall Street JournalNews
NNVC
1.490
+2.76%
0.040
Weekly Report: what happened at NNVC last week (1209-1213)?
Weekly Report · 5d ago
Weekly Report: what happened at NNVC last week (1202-1206)?
Weekly Report · 12/09 12:15
Weekly Report: what happened at NNVC last week (1125-1129)?
Weekly Report · 12/02 12:16
Weekly Report: what happened at NNVC last week (1118-1122)?
Weekly Report · 11/25 12:04
Weekly Report: what happened at NNVC last week (1111-1115)?
Weekly Report · 11/18 12:00
Weekly Report: what happened at NNVC last week (1104-1108)?
Weekly Report · 11/11 12:19
Weekly Report: what happened at NNVC last week (1028-1101)?
Weekly Report · 11/04 12:14
Weekly Report: what happened at NNVC last week (1021-1025)?
Weekly Report · 10/28 12:04
Weekly Report: what happened at NNVC last week (1014-1018)?
Weekly Report · 10/21 11:58
Weekly Report: what happened at NNVC last week (1007-1011)?
Weekly Report · 10/14 12:38
Weekly Report: what happened at NNVC last week (0930-1004)?
Weekly Report · 10/07 12:23
Weekly Report: what happened at NNVC last week (0923-0927)?
Weekly Report · 09/30 12:13
NanoViricides files annual report on Form 10-K
TipRanks · 09/30 10:40
NanoViricides says made ‘significant progress’ in NV-387 regulatory advancement
TipRanks · 09/30 10:40
NanoViricides plans to advance NV-387 into Phase II clinical trials
TipRanks · 09/30 10:40
NanoViricides Advances NV-387 Antiviral Drug, Prepares for Phase II Clinical Trials for RSV and MPOX Treatment
Benzinga · 09/30 10:35
NanoViricides Secures First Rights To TheraCour's Antiviral Developments, Eyes Phase II Trials For Lead Drug
Benzinga · 09/26 10:36
Weekly Report: what happened at NNVC last week (0916-0920)?
Weekly Report · 09/23 12:12
Weekly Report: what happened at NNVC last week (0909-0913)?
Weekly Report · 09/16 11:58
Weekly Report: what happened at NNVC last week (0902-0906)?
Weekly Report · 09/09 12:14
More
Webull provides a variety of real-time NNVC stock news. You can receive the latest news about Nanoviricides through multiple platforms. This information may help you make smarter investment decisions.
About NNVC
NanoViricides, Inc. is a clinical-stage company that is creating special purpose nanomaterials for antiviral therapy. Its nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. It is focused on advancing NV-387 into Phase II human clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 (API NV-387) is its nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is its other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.